Key Takeaways
- ACXP shares jumped more than 218% following the reveal of a clinical trial program for ibezapolstat, its primary antibiotic candidate.
- Phase 2 data demonstrated an impressive 96% cure rate for C. difficile infection, with no patients experiencing recurrence after successful treatment.
- A 20-patient open-label pilot study targeting recurrent CDI is now underway, setting the foundation for a Phase 3 registration trial.
- Both U.S. and European health authorities have provided approval for Acurx to proceed with international Phase 3 clinical studies.
- Annual net losses for 2025 decreased to $8.0 million from $14.1 million, while available cash rose to $7.6 million.
Acurx Pharmaceuticals (ACXP) delivered one of biotech’s most dramatic performance stories this year. Shares skyrocketed more than 218% across five trading sessions after the firm unveiled its clinical trial initiative for ibezapolstat, a novel antibiotic designed to combat C. difficile infection.
Acurx Pharmaceuticals, Inc., ACXP
The primary catalyst arrived on Monday with news that positioned the company for Phase 3 development. By Friday’s opening bell, shares tacked on an additional 3.59% during pre-market hours following the release of fourth-quarter financial results.
C. difficile infection, commonly abbreviated as CDI, represents a stubborn bacterial condition affecting the digestive system. Patients who experience three or more episodes annually face limited therapeutic choices and persistent recurrence challenges.
The Phase 2 clinical data for ibezapolstat provided compelling evidence for investors. The compound achieved a 96% clinical cure rate among 26 participants suffering from acute CDI. The most remarkable finding — zero cured patients experienced relapse throughout the observation window.
This dual capability of treating active infection while preventing recurrence is what Acurx considers ibezapolstat’s key differentiator. Existing therapies typically address the immediate infection without preventing subsequent episodes.
The biotech firm is now initiating a 20-patient open-label pilot study concentrated on multiply-recurrent CDI cases — specifically patients who’ve experienced at least three episodes within the preceding year. Data from this pilot will inform the architecture of the comprehensive Phase 3 registration trial.
Green Light from Global Regulators
Among this week’s most significant developments was verification that regulatory agencies in both the United States and Europe have authorized Acurx to commence international Phase 3 clinical studies. This simultaneous regulatory alignment eliminates substantial uncertainty for a small-capitalization biotechnology company.
The confirmation also demonstrates that the company’s strategy extends beyond domestic borders — international expansion is integrated into the framework from inception.
In February 2026, Acurx secured fresh patent protection for its Pol IIIC inhibitor technology, extending coverage until December 2039. This provides extensive intellectual property protection should the therapeutic reach commercialization.
Fourth Quarter Results: Improving Loss Profile
Financially, Acurx disclosed a Q4 2025 loss of $5.32 per share, exceeding the $3.29 loss recorded in Q4 2024. However, the annual perspective presents a more encouraging narrative.
Across the entirety of 2025, net losses totaled $8.0 million versus $14.1 million in 2024 — representing substantial improvement. Research and development expenditures declined to $0.3 million from $0.8 million, while general and administrative costs fell to $1.3 million from $2.0 million.
The company’s cash position also strengthened. Acurx closed December 31, 2025 with $7.6 million in available funds, compared to $3.7 million twelve months prior. This represents a more robust financial foundation entering a new trial phase.
Currently, two Wall Street analysts assign ACXP a Moderate Buy rating, with a consensus 12-month price target of $17.50.
Following Friday morning’s earnings disclosure, shares were trading up 3.59% in pre-market activity after the company confirmed the launch of its new rCDI trial program.
